Rigel Pharmaceuticals
RIGL
121 hedge funds and large institutions have $528M invested in Rigel Pharmaceuticals in 2017 Q4 according to their latest regulatory filings, with 28 funds opening new positions, 52 increasing their positions, 21 reducing their positions, and 15 closing their positions.
319% more call options, than puts
Call options by funds: $1.43M | Put options by funds: $341K
148% more repeat investments, than reductions
Existing positions increased: 52 | Existing positions reduced: 21
90% more capital invested
Capital invested by funds: $278M → $528M (+$250M)
87% more first-time investments, than exits
New positions opened: 28 | Existing positions closed: 15
12% more funds holding
Funds holding: 108 → 121 (+13)
0.51% more ownership
Funds ownership: 8.77% → 9.29% (+0.51%)
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
+$19.9M |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$14.7M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
+$12.6M |
| 4 |
BC
Boxer Capital
San Diego,
California
|
+$12M |
| 5 |
Millennium Management
New York
|
+$10.9M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
-$4.63M |
| 2 |
SCM
Sio Capital Management
New York
|
-$2.58M |
| 3 |
RPAM
Rhenman & Partners Asset Management
Stockholm,
Sweden
|
-$1.59M |
| 4 |
Wells Fargo
San Francisco,
California
|
-$1.24M |
| 5 |
GTC
Ghost Tree Capital
New York
|
-$1.05M |
RIGL Hedge Fund Activity: Q4 2017 in Review
121 of the 4,419 institutional investors tracked by Wall St. Rank reported a position in Rigel Pharmaceuticals (RIGL) for Q4 2017, worth a combined $528M — up 90% from $278M a quarter earlier.
Buyers outnumbered sellers: 28 funds opened new RIGL positions and 15 closed out — a net gain of 13 holders — while 52 added to existing stakes and 21 trimmed.
The largest buyer was Wellington Management Group, adding an estimated $19.9M. The largest seller was Great Point Partners, cutting an estimated $4.63M.
- 121 institutional investors held Rigel Pharmaceuticals (RIGL) as of Q4 2017, up from 108 in Q3 2017.
- Funds reported $528M of Rigel Pharmaceuticals stock for Q4 2017, up 90% quarter-over-quarter.
- 28 funds opened new Rigel Pharmaceuticals positions in Q4 2017 and 15 closed out, a net change of +13 holders.
- The largest Rigel Pharmaceuticals buyer in Q4 2017 was Wellington Management Group, an estimated $19.9M added.
- The largest Rigel Pharmaceuticals seller in Q4 2017 was Great Point Partners, an estimated $4.63M sold.
Based on aggregated 13F filings for Q4 2017.